The Federal Trade Commission (FTC) has initiated legal actions against the three largest Pharmacy Benefit Managers (PBMs) over allegations of inflating insulin prices. This move comes amid mounting concerns about the high cost of insulin, crucial for millions of Americans with diabetes. The FTC’s Bureau of Competition’s deputy director, Rahul Rao, emphasized that the sharp increase in insulin prices over the past decade has significantly impacted vulnerable patients, attributing part of the blame to the actions of these powerful PBMs.
For detailed information on the ongoing legal proceedings and the implications for the pharmaceutical industry, refer to the original article.